Incyte Clinical Trials: 282 Led Studies

Archive historyOct 2022 to Jun 2026

103 recorded changes across Incyte trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 39 of these trials. One is shown below.

Status changeStatus moved to active not recruiting from recruitingNCT06516952 · recorded 1 Jun 2026

Track to read them

+99 more recorded changes · Track a drug to see every change the night it lands

Start tracking drugs

Most active programmes

The drugs appearing most often across Incyte's recently active trials. Comparator arms are excluded.

Ruxolitinib Cream11 trials
Povorcitinib10 trials
Ruxolitinib10 trials
Vehicle Cream8 trials
INCB1236676 trials
Tafasitamab5 trials

Upcoming readouts

Next primary completion dates among Incyte's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Aug 2026TRuE-VIP1: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With …Phase 3
Oct 2026Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis…Phase 3
Apr 2027MAESTRA 1: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Over…Phase 2
Apr 2027A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Ol…Phase 3
Jul 2027Progress: To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplas…Phase 2
Aug 2027Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previo…Phase 2

Top therapeutic areas

Conditions studied most often across Incyte's recently active trials.

Solid Tumors8 trials
Atopic Dermatitis6 trials
Chronic Graft-versus-host-disease5 trials
Hidradenitis Suppurativa (HS)5 trials
Myeloproliferative Neoplasms5 trials
NonSegmental Vitiligo4 trials

Incyte trials

The 50 most significant of Incyte's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveNCT05879822INCB099280	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	73 est.	22 Jul 2026
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid TumorsNCT06873789INCB177054	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	9 est.	30 Jul 2026
TRuE-VIP1A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoNCT06548360Ruxolitinib Cream	Phase 3	Locked · track to reveal	OngoingRecruiting	180 est.	10 Aug 2026
frontMINDTafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092Tafasitamab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	899 est.	1 Sept 2026
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult ParticipantsNCT07588139Povorcitinib	Phase 1	Locked · track to reveal	OngoingRecruiting	24 est.	3 Sept 2026
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaNCT05888844INCB099280	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	63 est.	28 Sept 2026
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225Ruxolitinib Cream	Phase 3	Locked · track to reveal	OngoingRecruiting	550 est.	9 Oct 2026
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211Ruxolitinib Cream	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	573 est.	9 Oct 2026
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult ParticipantsNCT07448155INCA033989	Phase 1	Locked · track to reveal	OngoingRecruiting	126 est.	19 Oct 2026
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)NCT06516952Povorcitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	349 est.	19 Oct 2026
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965Povorcitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	346 est.	19 Oct 2026
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)NCT04509700Parsaclisib	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	112 est.	5 Nov 2026
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443povorcitinib	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	247 est.	20 Nov 2026
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaNCT07049575Ruxolitinib Cream	Phase 1	Locked · track to reveal	OngoingRecruiting	24 est.	9 Dec 2026
STOP-HS LTEA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999Povorcitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	617 est.	26 Dec 2026
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06179160INCB161734	Phase 1	Locked · track to reveal	OngoingRecruiting	710 est.	1 Jan 2027
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal DiseaseNCT07559396INCB123667	Phase 1	Locked · track to reveal	OngoingRecruiting	16 est.	4 Jan 2027
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsNCT05836324INCA33890	Phase 1	Locked · track to reveal	OngoingRecruiting	408 est.	13 Jan 2027
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT06818812INCB186748	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	30 est.	27 Mar 2027
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic ImpairmentNCT07559474INCB123667	Phase 1	Locked · track to reveal	OngoingRecruiting	16 est.	13 Apr 2027
MAESTRA 1A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07023627INCB123667	Phase 2	Locked · track to reveal	OngoingRecruiting	160 est.	27 Apr 2027
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoNCT06804811Ruxolitinib Cream	Phase 3	Locked · track to reveal	OngoingRecruiting	250 est.	30 Apr 2027
LIMBERSafety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsNCT04279847INCB057643	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	140 est.	30 Apr 2027
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseNCT06388564Axatilimab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	130 est.	1 Jun 2027
Study of INCB123667 in Subjects With Advanced Solid TumorsNCT05238922INCB0123667	Phase 1	Locked · track to reveal	OngoingRecruiting	604 est.	27 Jul 2027
ProgressTo Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaNCT05090891INCB000928	Phase 2	Locked · track to reveal	OngoingRecruiting	98 est.	30 Jul 2027
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database AnalysisNCT06627335Ruxolitinib Cream	—	Not yet scored	OngoingRecruiting	5,621 est.	15 Aug 2027
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With TafasitamabNCT06465433Tafasitamab	Phase 2	Locked · track to reveal	OngoingRecruiting	25 est.	29 Aug 2027
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersNCT07104565INCA000585	Phase 2	Locked · track to reveal	OngoingRecruiting	56 est.	23 Sept 2027
AXemplify-357A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseNCT06585774INCA034176	Phase 3	Locked · track to reveal	OngoingRecruiting	240 est.	28 Sept 2027
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibNCT02955940Ruxolitinib	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	10 est.	30 Sept 2027
THRIVEObservational Study for Patients at Risk for Chronic Graft-Versus-Host DiseaseNCT05919511Non-Interventional	—	Not yet scored	OngoingRecruiting	1,500 est.	15 Oct 2027
STOP-LTRRollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibNCT06855498povorcitinib	Phase 3	Locked · track to reveal	OngoingRecruiting	600 est.	28 Feb 2028
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsNCT05936359INCA033989	Phase 1	Locked · track to reveal	OngoingRecruiting	225 est.	29 Feb 2028
A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsNCT07008118INCA035784	Phase 1	Locked · track to reveal	OngoingRecruiting	120 est.	14 Mar 2028
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT07213973Povorcitinib	Phase 2	Locked · track to reveal	OngoingRecruiting	40 est.	25 Mar 2028
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyNCT06821542INCA034176	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	9 est.	31 May 2028
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesNCT07195916INCA036873	Phase 1	Locked · track to reveal	OngoingRecruiting	280 est.	18 Aug 2028
DAWN-303A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaNCT07522073INCB161734	Phase 3	Locked · track to reveal	OngoingRecruiting	588 est.	15 Sept 2028
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsNCT06313593INCB160058	Phase 1	Locked · track to reveal	OngoingRecruiting	186 est.	9 Oct 2028
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsNCT06034002INCA033989	Phase 1	Locked · track to reveal	OngoingRecruiting	290 est.	29 Oct 2028
MAESTRA 2Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionNCT07214779INCB123667	Phase 3	Locked · track to reveal	OngoingRecruiting	466 est.	15 Nov 2028
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal CancerNCT07284849INCA33890	Phase 3	Locked · track to reveal	OngoingRecruiting	700 est.	29 Dec 2028
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)NCT07124078INCA034176	Phase 2	Locked · track to reveal	OngoingRecruiting	60 est.	31 Jan 2029
EXCALIBUR-ET2A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaNCT07623200INCA033989	Phase 3	Not yet scored	OngoingNot yet recruiting	426 est.	15 Jun 2029
Study of INCA036978 in Participants With Myeloproliferative NeoplasmsNCT07441694INCA036978	Phase 1	Locked · track to reveal	OngoingRecruiting	218 est.	24 May 2030
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)NCT06615050Tacrolimus (Tac)	Phase 3	Locked · track to reveal	OngoingRecruiting	572 est.	17 Jan 2031
OPERA-1Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control PopulationNCT06259669Ruxolitinib Cream	—	Not yet scored	OngoingRecruiting	958 est.	1 Aug 2032
TRuE-AD5A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisNCT06832618Ruxolitinib	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	159 est.	13 Jul 2026
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDNCT06843408INCA034176	Phase 1	Locked · track to reveal	OngoingRecruiting	30 est.	3 Jul 2026

View all trials282

frontMIND: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Phase 3Active, not recruitingNCT04824092 ↗

Primary completion: Sept 2026; estimated
Enrollment: 899; estimated
Start: May 2021; Incyte Corporation

Conditions

Diffuse Large B-cell Lymphoma

Interventions

Tafasitamab
Lenalidomide
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine
Prednisone
Tafasitamab placebo

Brief summary

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Oct 2025

Completion date move · 1

Enrollment change · 1

Status change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2Active, not recruitingNCT04509700 ↗

Primary completion: Nov 2026; estimated
Enrollment: 112; estimated
Start: Aug 2020; Incyte Corporation

Conditions

B-Cell Malignancies

Interventions

Parsaclisib
parsaclisib + itacitinib
parsaclisib + ruxolitinib
parsaclisib + ibrutinib

Brief summary

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Jan 2025

Completion date move · 3

Status change · 3

Enrollment change · 2

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

STOP-HS LTE: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3Active, not recruitingNCT06212999 ↗

Primary completion: Dec 2026; estimated
Enrollment: 617; estimated
Start: Jan 2024; Incyte Corporation

Conditions

Hidradenitis Suppurativa (HS)

Interventions

Povorcitinib

Brief summary

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Status change · 1

Enrollment change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

LIMBER: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Phase 1Active, not recruitingNCT04279847 ↗

Primary completion: Apr 2027; estimated
Enrollment: 140; estimated
Start: Feb 2021; Incyte Corporation

Conditions

Myelofibrosis
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
Myeloproliferative Neoplasm
Relapsed or Refractory Primary Myelofibrosis
Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
ET (Essential Thrombocythemia)

Interventions

INCB057643
Ruxolitinib

Brief summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Mar 2026

Enrollment change · 3

Completion date move · 2

Status change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Phase 2Active, not recruitingNCT06388564 ↗

Primary completion: Jun 2027; estimated
Enrollment: 130; estimated
Start: Oct 2024; Incyte Corporation

Conditions

Chronic Graft-versus-host-disease

Interventions

Axatilimab
Ruxolitinib
Corticosteroids

Brief summary

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jun 2026

Status change · 2

Enrollment change · 1

Completion date move · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1RecruitingNCT05238922 ↗

Primary completion: Jul 2027; estimated
Enrollment: 604; estimated
Start: Jul 2022; Incyte Corporation

Conditions

Solid Tumors

Interventions

INCB0123667
Palbociclib
Bevacizumab
Olaparib
Paclitaxel
Ribociclib
Fulvestrant

Brief summary

This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Sept 2025

Completion date move · 3

Enrollment change · 3

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

Progress: To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Phase 2RecruitingNCT05090891 ↗

Primary completion: Jul 2027; estimated
Enrollment: 98; estimated
Start: May 2022; Incyte Corporation

Conditions

Fibrodysplasia Ossificans Progressiva (FOP)

Interventions

INCB000928
Placebo

Brief summary

This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jan 2026

Completion date move · 5

Enrollment change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Phase 2Active, not recruitingNCT02955940 ↗

Primary completion: Sept 2027; estimated
Enrollment: 10; estimated
Start: Nov 2016; Incyte Corporation

Conditions

Pancreatic Cancer
Colorectal Cancer (CRC)
Breast Cancer
Lung Cancer

Interventions

Ruxolitinib
Capecitabine
Regorafenib

Brief summary

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2025

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1RecruitingNCT06034002 ↗

Primary completion: Oct 2028; estimated
Enrollment: 290; estimated
Start: Dec 2023; Incyte Corporation

Conditions

Myeloproliferative Neoplasms

Interventions

INCA033989
Ruxolitinib

Brief summary

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Enrollment change · 2

Status change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3RecruitingNCT07284849 ↗

Primary completion: Dec 2028; estimated
Enrollment: 700; estimated
Start: Mar 2026; Incyte Corporation

Conditions

CRC (Colorectal Cancer)

Interventions

INCA33890
Placebo
Bevacizumab
FOLFOX

Brief summary

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Phase 3RecruitingNCT06615050 ↗

Primary completion: Jan 2031; estimated
Enrollment: 572; estimated
Start: Apr 2025; Incyte Corporation

Conditions

Graft-versus-host Disease (GVHD)

Interventions

Tacrolimus (Tac)
Methotrexate (MTX)
Ruxolitinib (Rux)
Cyclophosphamide
Mycophenolate mofetil (MMF)

Brief summary

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2025

Status change · 1

Completion date move · 1

Track Incyte drugs to see every change the night it lands.

Start tracking drugs

OPERA-1: Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

–RecruitingNCT06259669 ↗

Primary completion: Aug 2032; estimated
Enrollment: 958; estimated
Start: Sept 2023; Incyte Corporation

Conditions

Pregnancy Related
Atopic Dermatitis

Interventions

Ruxolitinib Cream

Brief summary

This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.